Biosidus expands biologics manufacturing capacity to boost global supply of agalsidase beta
Executive summary: Biosidus announced the expansion of its biologics manufacturing capacity to increase global supply of agalsidase beta. The expansion addresses growing demand for Fabry disease therapy and enhances Biosidus's competitiveness in the biologics sector.
Who is involved: Biosidus (Argentine biotech company), agalsidase beta product, global healthcare supply chain.
Likely next: The company will ramp up production at the new bioreactor facility and may pursue additional regulatory approvals and distribution agreements.
Biosidus, an Argentine biotechnology firm with over four decades of experience, announced the expansion of its biologics production facilities to strengthen worldwide availability of agalsidase beta, an enzyme replacement therapy for Fabry disease. The move aims to meet rising demand and improve supply chain reliability for this critical therapeutic. By scaling up its bioreactor operations, Biosidus positions itself to capture greater share in the biologics market while addressing patient access needs.
Timeline
- — Biosidus amplía su capacidad de fabricación de productos biológicos (PR Newswire)
- — Biosidus erweitert seine Produktionskapazitäten für Biologika und stärkt seine weltweiten Lieferkapazitäten für Agalsidase beta (PR Newswire)
Analysis — what this means
Sectors affected
- biologics manufacturing
- enzyme replacement therapy (Fabry disease)
Sources
- Biosidus amplía su capacidad de fabricación de productos biológicos — PR Newswire
- Biosidus erweitert seine Produktionskapazitäten für Biologika und stärkt seine weltweiten Lieferkapazitäten für Agalsidase beta — PR Newswire